Nano-X Imaging Ltd.
Nano-X Imaging Ltd. develops medical imaging systems and related software for radiology and healthcare providers. Its business centers on the Nanox.ARC imaging system, AI-enabled imaging software, and radiology services delivered through a multi-segment structure that also includes healthcare IT capabilities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCapital equipment and deployed imaging systems sold through direct and distribution channels.
AI-enabled imaging software, analytics, and workflow tools used by imaging providers.
Scan-related services and network-based imaging delivery offered to healthcare customers.
Healthcare information technology products and services added through acquisition.
Customers
Customers include hospitals, orthopedic centers, integrated delivery networks, and other imaging providers that use the company’s systems and software in clinical settings. The company also serves distributors, resellers, and healthcare IT buyers that help broaden deployment across geographies and customer types. Its products are sold into healthcare workflows where buyers seek imaging access, diagnostic capability, and software-driven operational efficiency.
Buy Nanox.ARC systems and related services to expand imaging access and diagnostic capacity.
Purchase imaging systems for specialty diagnostic use cases and local scan delivery.
Use deployed systems across larger care networks where multi-site imaging access matters.
Buy or place products to extend commercial reach in the U.S., Latin America, and other markets.
Acquire software and IT solutions for imaging workflow, data management, and clinical operations.
Strategy
Nanox is focused on broadening commercial deployment of its imaging platform through distribution agreements, clinical pilots, and installed-system placements. It is also building a network-based model around imaging access while expanding the AI and software layer that can be sold alongside hardware and services. The company’s recent emphasis on third-party manufacturing and partner-led distribution shows a strategy built around reach, scalability, and external channel leverage.
The U.S. is the largest addressable market and a key reference market for clinical adoption.
Deployed systems and network scans create the operating base for recurring customer relationships.
Software can extend the platform beyond hardware sales and improve customer stickiness.
Third-party manufacturing can reduce operational complexity and support product availability.
Geography
The company is headquartered in the United States but operates with a meaningful international footprint, including Israel-linked operations and manufacturing activities in South Korea. Recent disclosures highlight commercial expansion in the U.S. and distribution development in Latin America, with Costa Rica cited as a market entry point. Its operating footprint matters because imaging hardware, software deployment, and supply chain execution are all tied to region-specific regulators, distributors, and manufacturing partners.
Risks
Nanox faces commercialization risk because its business depends on customer adoption of a relatively new imaging platform and on distributor execution in each market. It also carries manufacturing and supply-chain risk, particularly where semiconductor and hardware production depend on external partners. In addition, the company is exposed to impairment risk, regulatory and clinical adoption risk, and the usual execution challenges of a medical technology platform business.
- Commercial adoption riskImpact: HighLikelihood: High
Revenue depends on hospitals and providers choosing a newer imaging platform over established alternatives.
Exposure - Supply-chain and manufacturing riskImpact: HighLikelihood: High
Chip production and hardware availability depend on qualified third-party partners and operating discipline.
Exposure: South Korea semiconductor operations and system supply
- Asset impairment riskImpact: HighLikelihood: High
Management disclosed reduced forecasts and impairment indicators in the AI solutions business unit.
Exposure: AI Solutions and Nanox ARC asset groups
- Distribution and channel riskImpact: MediumLikelihood: High
Growth depends on partners that may not generate expected customer placements or reseller traction.
Exposure
Accounting
Judgemental itemsDifferent product and service arrangements may recognize revenue at different times.
Impact: Affects quarter-to-quarter comparability and deferred revenue balances
Management identified impairment indicators in AI Solutions and used discounted cash flow testing.
Impact: Can materially reduce asset carrying values and increase non-cash charges
Acquisition-related earnouts must be remeasured as expectations change.
Impact: Can create volatile non-cash fair value adjustments
Upfront billing or service obligations can defer revenue into future periods.
Impact: Influences timing of recognized sales and contract liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
Varex Imaging Corp
VREX · Electronic Components, NEC
Varex Imaging Corp designs and manufactures X-ray imaging components and related systems used inside medical, security, and industrial inspection equipment.
Nanobiotix S.A.
NBTX · Pharmaceutical Preparations
RadNet, Inc.
RDNT · Services-Medical Laboratories
Streamex Corp.
STEX · Security & Commodity Brokers, Dealers, Exchanges & Services
NanoViricides, Inc
NNVC · Pharmaceutical Preparations
SuperX AI Technology Ltd
SUPX · Services-Management Consulting Services
SuperX AI Technology Ltd is an AI infrastructure and services company focused on hardware, software, and operational support for AI data centers.
Last updated: 28/09/2026